7 research outputs found
ΠΠ ΠΠΠ¦ΠΠΠ« Π’ΠΠ ΠΠΠΠ ΠΠ’ΠΠΠΠ§ΠΠ‘ΠΠΠΠ ΠΠΠ ΠΠΠ’ΠΠ’Π Π ΠΠΠ’Π‘ΠΠΠ ΠΠΠΠ ΠΠ‘Π’Π Π ΠΠ‘ΠΠΠΠ’Π Π‘ΠΠΠ ΠΠΠΠΠΠ«Π₯ ΠΠ ΠΠΠ‘Π’ΠΠΠΠΠΠΠ Π ΠΠΠ’ΠΠΠΠΠΠΠ ΠΠΠΠΠΠΠΠΠΠΠ―
The article contains data on the key links in the pathogenesis of atopic dermatitis in children. The authors of the article have covered modern approaches to topical therapy of atopic dermatitis in children. Modern algorithms of proactive therapy and control over the course of the disease are presented.ΠΡΠΈΠ²Π΅Π΄Π΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΎΒ ΠΊΠ»ΡΡΠ΅Π²ΡΡ
Π·Π²Π΅Π½ΡΡΡ
ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠ° ΡΒ Π΄Π΅ΡΠ΅ΠΉ. ΠΡΠ²Π΅ΡΠ΅Π½Ρ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Ρ ΠΊΒ ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠ° ΡΒ Π΄Π΅ΡΠ΅ΠΉ. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ Π°Π»Π³ΠΎΡΠΈΡΠΌΡ ΠΏΡΠΎΠ°ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΒ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π½Π°Π΄ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ
Π‘ΠΠ‘Π’ΠΠΠΠΠ― Π’ΠΠ ΠΠΠΠ― ΠΠ‘ΠΠ ΠΠΠΠ Π ΠΠΠ’Π‘ΠΠΠ ΠΠΠΠ ΠΠ‘Π’Π (Π§ΠΠ‘Π’Π¬ I)
We include a review of modern methods of systemic therapy of psoriasis in children, indications for which are moderate and severe forms of psoriasis with PASI 10, skin pathological process that is uncontrollable with topical drugs, skin lesions with functional localization (lesions of genitals, palms and soles, facial skin), erythrodermic psoriasis, pustular psoriasis, psoriatic arthritis. We provide information on the techniques of narrow-band phototherapy (UVB 311 nm) that are used in the treatment of psoriasis in children. We provide data on efficacy, safety, necessary monitoring of clinical and laboratory indicators, peculiarities of vaccination during treatment of children with acitretin, methotrexate, cyclosporine.ΠΡΠΈΠ²ΠΎΠ΄ΠΈΡΡΡ ΠΎΠ±Π·ΠΎΡ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π° Π²Β Π΄Π΅ΡΡΠΊΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅, ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΡΠΌΠΈ Π΄Π»Ρ ΠΊΠΎΡΠΎΡΠΎΠΉ ΡΠ²Π»ΡΡΡΡΡ ΡΡΠ΅Π΄Π½Π΅ΡΡΠΆΠ΅Π»ΡΠ΅ ΠΈΒ ΡΡΠΆΠ΅Π»ΡΠ΅ ΡΠΎΡΠΌΡ ΠΏΡΠΎΡΠΈΠ°Π·Π° ΡΒ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠΌ PASI 10, ΠΊΠΎΠΆΠ½ΡΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΎΡΠ΅ΡΡ, Π½Π΅Β ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΠ΅ΠΌΡΠΉ Π½Π°ΡΡΠΆΠ½ΡΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ, ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΊΠΎΠΆΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ (ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠ»ΠΎΠ²ΡΡ
ΠΎΡΠ³Π°Π½ΠΎΠ², Π»Π°Π΄ΠΎΠ½Π΅ΠΉ ΠΈΒ ΠΏΠΎΠ΄ΠΎΡΠ², ΠΊΠΎΠΆΠΈ Π»ΠΈΡΠ°), ΡΡΠΈΡΡΠΎΠ΄Π΅ΡΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΎΡΠΈΠ°Π·, ΠΏΡΡΡΡΠ»Π΅Π·Π½ΡΠΉ ΠΏΡΠΎΡΠΈΠ°Π·, ΠΏΡΠΎΡΠΈΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΡΡΡΠΈΡ. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎΒ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ°Ρ
ΡΠ·ΠΊΠΎΠΏΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΡΠΎΡΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ (Π£Π€B 311 Π½ΠΌ), ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΡ
Π²Β Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π° Π²Β Π΄Π΅ΡΡΠΊΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅. ΠΡΠΈΠ²ΠΎΠ΄ΡΡΡΡ Π΄Π°Π½Π½ΡΠ΅ ΠΎΠ±Β ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ, Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΠΌ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π΅ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ
Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Π²ΠΎΒ Π²ΡΠ΅ΠΌΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄Π΅ΡΠ΅ΠΉ Π°ΡΠΈΡΡΠ΅ΡΠΈΠ½ΠΎΠΌ, ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠΎΠΌ, ΡΠΈΠΊΠ»ΠΎΡΠΏΠΎΡΠΈΠ½ΠΎΠΌ
Π‘ΠΈΡΡΠ΅ΠΌΠ½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΡΠΎΡΠΈΠ°Π·Π° Π² Π΄Π΅ΡΡΠΊΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ (ΡΠ°ΡΡΡ II): Π²ΠΎΠΏΡΠΎΡΡ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
The authors present an overview of the present day knowledge of methods of biological therapy used for treatment of severe psoriasis at an early age. Data is presented on efficiency, safety, required monitoring of clinical and laboratory performance, specifics of vaccination during the treatment of children with genetically engineered biological drugs. Data is presented on the authorsβ own clinical observations of 10 adolescents who were administered the preparation of ustekinumab. The objective of the observational study was assessment of efficiency and safety of application of ustekinumab for treatment of severe psoriasis with children over 12 years of age. Materials and Methods. The observation covered 10 children, their average age being 15Β±2.8 years old, the PASI index 39.3Β±9.5, who were administered ustekinumab at a dose of 45 mg under a standard administration regimen. Results. The therapeutic effect was assessed based on the PASI index, which was found to decrease by 75% with 6 adolescents, and by 90% with 4 adolescents as soon as by week 14 of the therapy. As is shown by the follow-up observation, the skin pathological process was completely resolved with 80% of adolescents after 3 injections of ustekinumab, and with 100% after 4 injections. Conclusion. The preparation of ustekinumab is efficient and safe for treatment of psoriasis at an early age. As based on the PASI index as the main criterion of assessment of treatment efficiency, ustekinumab (Stelara) is the medicine of choice for treatment of severe forms of the disease from the age of 12 years old.ΠΠ²ΡΠΎΡΡ ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡ ΠΎΠ±Π·ΠΎΡ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
Π΄Π°Π½Π½ΡΡ
ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π°Ρ
Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠΆΠ΅Π»ΡΡ
ΡΠΎΡΠΌ ΠΏΡΠΎΡΠΈΠ°Π·Π° Π² Π΄Π΅ΡΡΠΊΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΎΠ± ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ, Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΠΌ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π΅ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ
Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Π²ΠΎ Π²ΡΠ΅ΠΌΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄Π΅ΡΠ΅ΠΉ Π³Π΅Π½Π½ΠΎ-ΠΈΠ½ΠΆΠ΅Π½Π΅ΡΠ½ΡΠΌΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ. ΠΡΠΈΠ²ΠΎΠ΄ΡΡΡΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π·Π° 10 ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠ°ΠΌΠΈ, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΠΌΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΡΡΡΠ΅ΠΊΠΈΠ½ΡΠΌΠ°Π±. Π¦Π΅Π»ΡΡ Π½Π°Π±Π»ΡΠ΄Π°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΈΠ»Π°ΡΡ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΡΡΡΠ΅ΠΊΠΈΠ½ΡΠΌΠ°Π± Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΡΡΠΆΠ΅Π»ΡΡ
ΡΠΎΡΠΌ ΠΏΡΠΎΡΠΈΠ°Π·Π° Ρ Π΄Π΅ΡΠ΅ΠΉ ΡΡΠ°ΡΡΠ΅ 12 Π»Π΅Ρ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 10 Π΄Π΅ΡΠ΅ΠΉ, ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΠΊΠΎΡΠΎΡΡΡ
ΡΠΎΡΡΠ°Π²ΠΈΠ» 15Β±2,8 Π³ΠΎΠ΄Π°, ΠΈΠ½Π΄Π΅ΠΊΡ PASI β 39,3Β±9,5, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΡΡΡΠ΅ΠΊΠΈΠ½ΡΠΌΠ°Π± Π² Π΄ΠΎΠ·Π΅ 45 ΠΌΠ³ ΠΏΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ ΡΡ
Π΅ΠΌΠ΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π’Π΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ Π±ΡΠ» ΠΎΡΠ΅Π½Π΅Π½ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΈΠ½Π΄Π΅ΠΊΡΠ° PASI, ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ Π½Π° 75% Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ Ρ 6 ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ², Π½Π° 90% Ρ 4 ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ² ΡΠΆΠ΅ ΠΊ 14-ΠΉ Π½Π΅Π΄Π΅Π»Π΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠ°ΡΠ°ΠΌΠ½Π΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ, ΡΡΠΎ ΠΏΠΎΠ»Π½ΠΎΠ΅ ΡΠ°Π·ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠΆΠ½ΠΎΠ³ΠΎ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π½Π°ΡΡΡΠΏΠΈΠ»ΠΎ Ρ 80% ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ² ΠΏΠΎΡΠ»Π΅ 3 ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΡΡΡΠ΅ΠΊΠΈΠ½ΡΠΌΠ°Π±Π° ΠΈ Ρ 100% ΠΏΠΎΡΠ»Π΅ 4 ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠ΅ΠΏΠ°ΡΠ°Ρ ΡΡΡΠ΅ΠΊΠΈΠ½ΡΠΌΠ°Π± ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΡΠΌ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ°Π·Π° Ρ Π΄Π΅ΡΠ΅ΠΉ. ΠΠΏΠΈΡΠ°ΡΡΡ Π½Π° ΠΈΠ½Π΄Π΅ΠΊΡ PASI ΠΊΠ°ΠΊ Π½Π° Π³Π»Π°Π²Π½ΡΠΉ ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ, ΡΡΡΠ΅ΠΊΠΈΠ½ΡΠΌΠ°Π± (Π‘ΡΠ΅Π»Π°ΡΠ°) ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ Π²ΡΠ±ΠΎΡΠ° Π² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠΆΠ΅Π»ΡΡ
ΡΠΎΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ 12-Π»Π΅ΡΠ½Π΅Π³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°
ΠΠ°ΡΡΠΆΠ½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠ° Π² Π΄Π΅ΡΡΠΊΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅: ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ Π²ΡΠ·ΠΎΠ²Ρ ΠΈ ΠΎΡΠ²Π΅ΡΡ
Atopic dermatitis (AD) is the most prevalent skin disease in the early childhood and is a considerable problem both for patients and members of their families and for the society on the whole. In most cases, AD requires a long-term therapy such as the use of anti-inflammatory drugs. Selective inhibitors of the synthesis and release of proinflammatory cytokines - topical calcineurin inhibitors (Tcis) - are now used to solve this problem, with pimecrolimus being one of them. Pimecrolimus has been thoroughly examined for the past decade in different clinical studies involving a total of over 4,000 infants (below 2 years of age). These studies demonstrated the efficacy and safety of pimecrolimus for AD in children provided it is used in a long-term therapy on an intermittent basis. Unlike topical corticosteroids, the long-term use of pimecrolimus is not associated with any risk of development of systemic immunosuppression, skin atrophy, skin barrier dysfunction or systemic absorption so it is safe even if applied to the most sensitive skin areas. In view of this, the authors make a conclusion that pimecrolimus used in the form of a cream is a safe and efficient drug for the treatment of infants aged over three months suffering from atopic dermatitis.ΠΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΉ Π΄Π΅ΡΠΌΠ°ΡΠΈΡ (ΠΠ) ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°ΠΌΡΠΌ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠΆΠΈ Π² ΡΠ°Π½Π½Π΅ΠΌ Π΄Π΅ΡΡΠΊΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΎΠΉ ΠΊΠ°ΠΊ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΠ»Π΅Π½ΠΎΠ² ΠΈΡ
ΡΠ΅ΠΌΠ΅ΠΉ, ΡΠ°ΠΊ ΠΈ Π΄Π»Ρ ΠΎΠ±ΡΠ΅ΡΡΠ²Π° Π² ΡΠ΅Π»ΠΎΠΌ. Π Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠ»ΡΡΠ°Π΅Π² ΠΠ ΡΡΠ΅Π±ΡΠ΅Ρ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ². ΠΠ»Ρ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΡΡΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡΡΡ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΡΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΡΠΈΠ½ΡΠ΅Π·Π° ΠΈ Π²ΡΡΠ²ΠΎΠ±ΠΎΠΆΠ΄Π΅Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² - ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΠΊΠ°Π»ΡΡΠΈΠ½Π΅Π²ΡΠΈΠ½Π° (Π’ΠΠ), ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΊΠΎΡΠΎΡΡΡ
ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΠΈΠΌΠ΅ΠΊΡΠΎΠ»ΠΈΠΌΡΡ. Π ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅Π³ΠΎ Π΄Π΅ΡΡΡΠΈΠ»Π΅ΡΠΈΡ ΠΏΠΈΠΌΠ΅ΠΊΡΠΎΠ»ΠΈΠΌΡΡ Π±ΡΠ» ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎ ΠΈΠ·ΡΡΠ΅Π½ Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
Ρ ΡΡΠ°ΡΡΠΈΠ΅ΠΌ Π² ΠΎΠ±ΡΠ΅ΠΉ ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΠΈ Π±ΠΎΠ»Π΅Π΅ 4000 Π΄Π΅ΡΠ΅ΠΉ ΡΠ°Π½Π½Π΅Π³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° (ΠΌΠ»Π°Π΄ΡΠ΅ 2 Π»Π΅Ρ). Π ΡΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
Π±ΡΠ»ΠΈ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΏΠΈΠΌΠ΅ΠΊΡΠΎΠ»ΠΈΠΌΡΡΠ° Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΠ Ρ Π΄Π΅ΡΠ΅ΠΉ ΠΏΡΠΈ ΡΡΠ»ΠΎΠ²ΠΈΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² ΠΈΠ½ΡΠ΅ΡΠΌΠΈΡΡΠΈΡΡΡΡΠ΅ΠΌ ΡΠ΅ΠΆΠΈΠΌΠ΅. Π ΠΎΡΠ»ΠΈΡΠΈΠ΅ ΠΎΡ ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄ΠΎΠ² Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΈΠΌΠ΅ΠΊΡΠΎΠ»ΠΈΠΌΡΡΠ° Π½Π΅ ΡΠ²ΡΠ·Π°Π½ΠΎ Ρ ΡΠΈΡΠΊΠΎΠΌ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΈΠΈ, Π°ΡΡΠΎΡΠΈΠΈ ΠΊΠΎΠΆΠΈ, Π½Π°ΡΡΡΠ΅Π½ΠΈΠ΅ΠΌ Π±Π°ΡΡΠ΅ΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΊΠΎΠΆΠΈ ΠΈΠ»ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ Π°Π±ΡΠΎΡΠ±ΡΠΈΠ΅ΠΉ ΠΈ, ΡΠ°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎ ΠΏΡΠΈ Π½Π°Π½Π΅ΡΠ΅Π½ΠΈΠΈ Π΄Π°ΠΆΠ΅ Π½Π° ΡΠ°ΠΌΡΠ΅ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΡΠ°ΡΡΠΊΠΈ ΠΊΠΎΠΆΠΈ. ΠΡΡ
ΠΎΠ΄Ρ ΠΈΠ· ΡΡΠΎΠ³ΠΎ Π°Π²ΡΠΎΡΡ Π΄Π΅Π»Π°ΡΡ Π²ΡΠ²ΠΎΠ΄ ΠΎ ΡΠΎΠΌ, ΡΡΠΎ ΠΏΠΈΠΌΠ΅ΠΊΡΠΎΠ»ΠΈΠΌΡΡ Π² Π²ΠΈΠ΄Π΅ ΠΊΡΠ΅ΠΌΠ° ΡΠ²Π»ΡΠ΅ΡΡΡ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΡΠΌ ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄Π΅ΡΠ΅ΠΉ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΡΡΠ°ΡΡΠ΅ ΡΡΠ΅Ρ
ΠΌΠ΅ΡΡΡΠ΅Π², ΡΡΡΠ°Π΄Π°ΡΡΠΈΡ
Π°ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΈΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ
Metabolic violation of adolescents with psoriasis
This article represents a survey-analytical study of interrelationship of psoriasis and metabolic syndrome of children. The research and analysis was carried out from publications in the markers of metabolic syndrome had been explored. Much attention had been focused on population, clinical, age group and gender peculiarities of these conditions in different countries